Ohio State Navbar

Directory

David M. Lucas, PhD


Staff photo

410 W 12th Ave
Columbus, OH 43210

Phone: (614) 685-5667

Email: lucas.194@osu.edu

 

Current OSU Appointment

Research Assistant Professor, Hematology

 

Degrees

1996 Ph.D., University of Wisconsin

 

Editorial Activities

2006 - present Leukemia Research
2006 - present Leukemia & Lymphoma
2006 - present Journal of Clinical Oncology
2006 - present Journal of Natural Products
2006 - present Blood
2006 - present Haematologica
 

Honors

1987 Ben Suffron Memorial Scholarship.
1987 - 1991 National Merit Scholarship.
1987 - 1991 Miami Alumni Merit Scholarship.
1990 Harvey Clayton Brill Scholarship.
1991 Wisconsin Alumni Research Foundation Fellowship.
1992 - 1995 Training Grant in Molecular Biology. National Institutes of Health.
1994 Presidential Awards Competition. Society of Leukocyte Biology.
1997 - 2000 National Research Service Award. F32, National Institutes of Health.
2004 V-Foundation-AACR Translational Grant Award Co-Investigator.
2007 American Cancer Society Institutional Seed Grant Recipient.
2011 Seed Grant. Viral Oncology Program, Comprehensive Cancer Center.
 

Journal Articles

McDowell MA; Lucas DM; Nicolet CM; Paulnock DM. "Differential utilization of IFN-gamma-responsive elements in two maturationally distinct macrophage cell lines.." Journal Of Immunology (Baltimore, Md.: 1950). Vol. 155, no. 10. (November 1995.): 4933-.

Lucas DM; Lokuta MA; McDowell MA; Doan JE; Paulnock DM. "Analysis of the IFN-gamma-signaling pathway in macrophages at different stages of maturation.." Journal Of Immunology (Baltimore, Md.: 1950). Vol. 160, no. 9. (May 1998.): 4337-.

Lucas DM; Rohrschneider LR. "A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development.." Blood. Vol. 93, no. 6. (March 1999.): 1922-.

Rohrschneider LR; Fuller JF; Wolf I; Liu Y; Lucas DM. "Structure, function, and biology of SHIP proteins.." Genes & Development. Vol. 14, no. 5. (March 2000.): 505-.

Wolf I; Lucas DM; Algate PA; Rohrschneider LR. "Cloning of the genomic locus of mouse SH2 containing inositol 5-phosphatase (SHIP) and a novel 110-kDa splice isoform, SHIPdelta.." Genomics. Vol. 69, no. 1. (October 2000.): 104-.

March ME; Lucas DM; Aman MJ; Ravichandran KS. "p135 src homology 2 domain-containing inositol 5'-phosphatase (SHIPbeta ) isoform can substitute for p145 SHIP in fcgamma RIIB1-mediated inhibitory signaling in B cells.." The Journal Of Biological Chemistry. Vol. 275, no. 39. (September 2000.): 29960-.

Byrd JC, Shinn C, Willis CR, Flinn IW, Lehman T, Sausville E, Lucas DM, Grever MR. "UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism." Exp Hematol. (January 2001.): -.

Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas DM, Reed JC. "The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction." Blood. Vol. 3, no. 99. (January 2002.): 1038-1043.

Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas DM, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA.. "Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia." Blood. (January 2003.): -.

Byrd JC; Lucas DM; Mone AP; Kitner JB; Drabick JJ; Grever MR. "KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.." Blood. Vol. 101, no. 11. (June 2003.): 4547-.

Aron JL; Parthun MR; Marcucci G; Kitada S; Mone AP; Davis ME; Shen T; Murphy T; Wickham J; Kanakry C; Lucas DM; Reed JC; Grever MR; Byrd JC. "Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.." Blood. Vol. 102, no. 2. (July 2003.): 652-.

Bains SK, Mone A, Yun Tso J,Lucas DM, Byrd JC, Weiner GJ, Green JM. "Mitochondria control of cell death induced by anti-HLA-DR antibodies." Leukemia. Vol. 17, no. 7. (January 2003.): 1357-1365.

Pavletic SZ; Bociek RG; Foran JM; Rubocki RJ; Kuszynski CA; Wisecarver JL; Hatcher L; Lucas DM; Byrd JC; Grever MR; Joshi SS; Hardiman P; Smith LM; McGuire TR; Bierman PJ; Vose JM; Armitage JO; Talmadge JE. "Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.." Transplantation. Vol. 76, no. 5. (September 2003.): 877-.

Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas DM, Grever MR, Byrd JC.. "Alemtuzumab is an Effective Therapy for Chronic Lymphocytic Leukemia with p53 Mutations and Deletions." Blood. (January 2004.): -.

Lucas DM; Davis ME; Parthun MR; Mone AP; Kitada S; Cunningham KD; Flax EL; Wickham J; Reed JC; Byrd JC; Grever MR. "The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.." Leukemia: Official Journal Of The Leukemia Society Of America, Leukemia Research Fund, U.K. Vol. 18, no. 7. (July 2004.): 1207-.

Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas DM, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC. "G3139, a BCL-2 antisense oligo-nucleotide, in AML.." Ann Hematol. (January 2004.): -.

Rush LJ; Raval A; Funchain P; Johnson AJ; Smith L; Lucas DM; Bembea M; Liu TH; Heerema NA; Rassenti L; Liyanarachchi S; Davuluri R; Byrd JC; Plass C. "Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets.." Cancer Research. Vol. 64, no. 7. (April 2004.): 2424-.

Raval A; Lucas DM; Matkovic JJ; Bennett KL; Liyanarachchi S; Young DC; Rassenti L; Kipps TJ; Grever MR; Byrd JC; Plass C. "TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 23, no. 17. (June 2005.): 3877-.

Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC. "Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.." Leukemia: Official Journal Of The Leukemia Society Of America, Leukemia Research Fund, U.K. Vol. 19, no. 7. (July 2005.): 1207-.

Byrd JC; Marcucci G; Parthun MR; Xiao JJ; Klisovic RB; Moran M; Lin TS; Liu S; Sklenar AR; Davis ME; Lucas DM; Fischer B; Shank R; Tejaswi SL; Binkley P; Wright J; Chan KK; Grever MR. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.." Blood. Vol. 105, no. 3. (February 2005.): 959-.

Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC;Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB. "Pentostatin in steroid-refractory acute graft-versus-host disease.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 23, no. 12. (April 2005.): 2661-.

Johnson AJ; Lucas DM; Muthusamy N; Smith LL; Edwards RB; De Lay MD; Croce CM; Grever MR; Byrd JC. "Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.." Blood. Vol. 108, no. 4. (August 2006.): 1334-.

Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA. "Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 24, no. 3. (January 2006.): 437-.

Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC. "Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 25, no. 7. (March 2007.): 799-.

Su X; Zhang L;Lucas DM; Davis ME; Knapp AR; Green-Church KB; Marcucci G; Parthun MR; Byrd JC; Freitas MA. "Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.." Analytical Biochemistry. Vol. 363, no. 1. (April 2007.): 22-.

Browning RL; Geyer SM; Johnson AJ; Jelinek DF; Tschumper RC; Call TG; Shanafelt TD; Zent CS; Bone ND; Dewald GW; Lin TS; Heerema NA; Grever MR; Kay NE; Byrd JC; Lucas DM. "Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.." Leukemia Research. Vol. 31, no. 12. (December 2007.): 1737-.

Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR. "Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.." Blood. Vol. 109, no. 2. (January 2007.): 399-.

Knapp AR; Ren C; Su X; Lucas DM; Byrd JC; Freitas MA; Parthun MR. "Quantitative profiling of histone post-translational modifications by stable isotope labeling.." Methods (San Diego, Calif.). Vol. 41, no. 3. (March 2007.): 312-.

Raval A; Tanner SM; Byrd JC; Angerman EB; Perko JD; Chen SS; Hackanson B; Grever MR; Lucas DM; Matkovic JJ; Lin TS; Kipps TJ; Murray F; Weisenburger D; Sanger W; Lynch J; Watson P; Jansen M; Yoshinaga Y; Rosenquist R; de Jong PJ; Coggill P; Beck S; Lynch H; de la Chapelle A; Plass C. "Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.." Cell. Vol. 129, no. 5. (June 2007.): 879-.

Hussain SR; Cheney CM; Johnson AJ; Lin TS; Grever MR; Caligiuri MA; Lucas DM; Byrd JC. "Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.." Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 13, no. 7. (April 2007.): 2144-.

Berdeja JG; Hess A; Lucas DM; O'Donnell P; Ambinder RF; Diehl LF; Carter-Brookins D; Newton S; Flinn IW. "Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.." Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 13, no. 8. (April 2007.): 2392-.

Motiwala T; Majumder S; Kutay H; Smith DS; Neuberg DS; Lucas DM; Byrd JC; Grever M; Jacob ST. "Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.." Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 13, no. 11. (June 2007.): 3174-.

Johnson AJ; Wagner AJ; Cheney CM; Smith LL;Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC. "Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.." British Journal Of Haematology. Vol. 139, no. 5. (December 2007.): 837-.

Grever MR; Lucas DM; Johnson AJ; Byrd JC. "Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.." Best Practice & Research. Clinical Haematology. Vol. 20, no. 3. (September 2007.): 545-.

Su X; Jacob NK; Amunugama R; Lucas DM; Knapp AR; Ren C; Davis ME; Marcucci G; Parthun MR; Byrd JC; Fishel R; Freitas MA. "Liquid chromatography mass spectrometry profiling of histones.." Journal Of Chromatography. B, Analytical Technologies In The Biomedical And Life Sciences. Vol. 850, no. 1-2. (May 2007.): 440-.

Hussain SR; Lucas DM; Johnson AJ; Lin TS; Bakaletz AP; Dang VX; Viatchenko-Karpinski S; Ruppert AS; Byrd JC; Kuppusamy P; Crouser ED; Grever MR. "Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.." Blood. Vol. 111, no. 6. (March 2008.): 3190-.

Lucas DM; Byrd JC. "Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 26, no. 14. (May 2008.): 2244-.

Su X; Lucas DM; Zhang L; Xu H; Zabrouskov V; Davis ME; Knapp AR; Young DC; Payne PR; Parthun MR; Marcucci G; Grever MR; Byrd JC; Freitas MA. "Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.." Proteomics. Vol. 9, no. 5. (March 2009.): 1197-.

Woyach JA; Lin TS; Lucas MS; Heerema N; Moran ME; Cheney C; Lucas DM; Wei L; Caligiuri MA; Byrd JC. "A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.." Leukemia: Official Journal Of The Leukemia Society Of America, Leukemia Research Fund, U.K. Vol. 23, no. 5. (May 2009.): 912-.

Lucas DM; Edwards RB; Lozanski G; West DA; Shin JD; Vargo MA; Davis ME; Rozewski DM; Johnson AJ; Su BN; Goettl VM; Heerema NA; Lin TS; Lehman A; Zhang X; Jarjoura D; Newman DJ; Byrd JC; Kinghorn AD; Grever MR. "The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.." Blood. Vol. 113, no. 19. (May 2009.): 4656-.

Lin TS; Naumovski L; Lecane PS; Lucas MS; Moran ME; Cheney C; Lucas DM; Phan SC; Miller RA; Byrd JC. "Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.." Leukemia & Lymphoma. Vol. 50, no. 12. (December 2009.): 1977-.

Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S, Lucas DM, Jacob ST. "PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells." J Biol Chem. (January 2009.): -.

Blum KA; Advani A; Fernandez L; Van Der Jagt R; Brandwein J; Kambhampati S; Kassis J; Davis M; Bonfils C; Dubay M; Dumouchel J; Drouin M; Lucas DM; Martell RE; Byrd JC. "Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.." British Journal Of Haematology. Vol. 147, no. 4. (November 2009.): 507-.

Blum KA; Hamadani M; Phillips GS; Lozanski G; Johnson AJ; Lucas DM; Smith LL; Baiocchi R; Lin TS; Porcu P; Devine SM; Byrd JC. "Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.." Leukemia & Lymphoma. Vol. 50, no. 3. (March 2009.): 349-.

Awan FT; Kay NE; Davis ME; Wu W; Geyer SM; Leung N; Jelinek DF; Tschumper RC; Secreto CR; Lin TS; Grever MR; Shanafelt TD; Zent CS; Call TG; Heerema NA; Lozanski G; Byrd JC;Lucas DM. "Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.." Blood. Vol. 113, no. 3. (January 2009.): 535-.

Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA. "Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.." Mabs. Vol. 1, no. 1. (January 2009.): 31-.

Blum W; Phelps MA; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM; Johnson A; Schaaf LJ; Byrd JC; Marcucci G; Grever MR. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.." Haematologica. Vol. 95, no. 7. (July 2010.): 1098-.

Blum KA; Liu Z; Lucas DM; Chen P; Xie Z; Baiocchi R; Benson DM; Devine SM; Jones J; Andritsos L; Flynn J; Plass C; Marcucci G; Chan KK; Grever MR; Byrd JC. "Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.." British Journal Of Haematology. Vol. 150, no. 2. (July 2010.): 189-.

Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL. "A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.." Cancer Chemotherapy And Pharmacology. Vol. 66, no. 1. (May 2010.): 151-.

Lucas DM; Still PC; Pérez LB; Grever MR; Kinghorn AD. "Potential of plant-derived natural products in the treatment of leukemia and lymphoma.." Current Drug Targets. Vol. 11, no. 7. (July 2010.): 812-.

Flynn JM, Andritsos L,Lucas, DM, Byrd JC. "Second malignancies in C-cell chromic lymphocytic leukemia: possible association with human papilloma virus." British Journal of Haematology. Vol. 3, no. 149. (January 2010.): 388-390.

Blum KA, Jund S-H, Johnson L, Lin Ts, Hsi Ed,Lucas, DM, Byrd JC, Cheson N, Bartlett L and for the Cancer and Leukemia Group B. "Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcRIIIa-158 V/F polymorphism." Annals of Oncology. (April 2010.): -.

Lucas DM; Alinari L; West DA; Davis ME; Edwards RB; Johnson AJ; Blum KA; Hofmeister CC; Freitas MA; Parthun MR; Wang D; Lehman A; Zhang X; Jarjoura D; Kulp SK; Croce CM; Grever MR; Chen CS; Baiocchi RA; Byrd JC. "The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo.." Plos One. Vol. 5, no. 6. (June 2010.): e10941-.

Hertlein E; Triantafillou G; Sass EJ; Hessler JD; Zhang X; Jarjoura D; Lucas DM; Muthusamy N; Goldenberg DM; Lee RJ; Byrd JC. "Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.." Blood. Vol. 116, no. 14. (October 2010.): 2554-.

Sanchez-Aguilera A; Rattmann I; Drew DZ; Müller LU; Summey V; Lucas DM; Byrd JC; Croce CM; Gu Y; Cancelas JA; Johnston P; Moritz T; Williams DA. "Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia.." Leukemia: Official Journal Of The Leukemia Society Of America, Leukemia Research Fund, U.K. Vol. 24, no. 1. (January 2010.): 97-.

Lucas, DM, Still PC, Pérez LB, Grever MR, Kinghorn AD. Curr Drug Targets. Vol. 11, no. 7. (July 2010.): 812-822.

Blum KA; Jung SH; Johnson JL; Lin TS; Hsi ED; Lucas DM; Byrd JC; Cheson BD; Bartlett NL. "Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.." Annals Of Oncology: Official Journal Of The European Society For Medical Oncology / ESMO. Vol. 21, no. 11. (November 2010.): 2246-.

Saradhi UV, Gupta SV, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas, DM, Grever MR, Phelps MA, Chan KK.. "Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry." AAPS. no. Epub ahead of print. (April 2011.): -.

Saradhi UV; Gupta SV; Chiu M; Wang J; Ling Y; Liu Z; Newman DJ; Covey JM; Kinghorn AD; Marcucci G; Lucas DM; Grever MR; Phelps MA; Chan KK. "Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.." The AAPS Journal. Vol. 13, no. 3. (September 2011.): 347-.

You J; Wang L; Saji M; Olesik SV; Ringel MD; Lucas DM; Byrd JC; Freitas MA. "High-sensitivity TFA-free LC-MS for profiling histones.." Proteomics. Vol. 11, no. 16. (August 2011.): 3326-.

Gupta SV; Sass EJ; Davis ME; Edwards RB; Lozanski G; Heerema NA; Lehman A; Zhang X; Jarjoura D; Byrd JC; Pan L; Chan KK; Kinghorn AD; Phelps MA; Grever MR; Lucas DM. "Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.." The AAPS Journal. Vol. 13, no. 3. (September 2011.): 357-.

Motiwala T; Zanesi N; Datta J; Roy S; Kutay H; Checovich AM; Kaou M; Zhong Y; Johnson AJ; Lucas DM; Heerema NA; Hagan J; Mo X; Jarjoura D; Byrd JC; Croce CM; Jacob ST. "AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.." Blood. Vol. 118, no. 23. (December 2011.): 6132-.

Chen SS; Claus R; Lucas DM; Yu L; Qian J; Ruppert AS; West DA; Williams KE; Johnson AJ; Sablitzky F; Plass C; Byrd JC. "Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.." Blood. Vol. 117, no. 3. (January 2011.): 862-.

Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Pan L, Chan KK, Kinghorn AD, Phelps MA, Grever MR, Lucas, DM. "Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells.." AAPS. no. Epub ahead of print. (May 2011.): -.

 

Reference Works

January 2000 Marcucci G, Bloomfield CD, Balcerzak SP, Korlas PJ, Stanley HR, Fingert H, Maghraby, EA, Lucas, DM, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Phase I Trial of Genasense (G3139, Genta, Inc.), A BCL-2 Antisense, in Refractory or relapsed Acute Leukemia." . : 513a
January 2001 Marcucci G, Byrd JC, Cataland SR, Fisher DB, Lucas, DM, Chan KK, Klisovic M, Young DC, Didier LA, Balcerzak SP, Frankel SR, Kraut EH, Bloomfield CD, Grever MR, Caligiuri MA."Clinical and Biological Activity of Genasense (G3139, Genta, Inc.), a BCL-2 Antisense, in Refractory or Relapsed Acute Leukemia: A Phase I Study" . : 216b
January 2001 Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Kourlas P, Lucas, DM, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Biologic Activity of G3139 (Genasense), a BCL-2 Antisense, in Refractory or Relapsed Acute Leukemia" . : 1149
January 2001 Bannerji R, Kitada S, Flinn IW, Pearson M, Lucas, DM, Grever MR, Reed JC, Byrd JC."Campath-1H Antibody Induces Transmembrane Signaling in vitro and in vivo in Patients with Chronic Lymphocytic Leukemia and Promotes Tumor Clearance in Part Through Caspase mediated Apoptosis" . : 808a
January 2001 Bannerji R, Flinn IW, Pearson M, Shinn C, Sickler J, Lucas M,Lucas, DM Byrd JC."Campath-1H Antibody Induces Transmembrane Signaling in Vivo in Patients with Chronic Lymphocytic Leukemia (CLL) and Promotes Tumor Clearance via a Caspase-9 Apoptotic Pathway" . : 1215a
January 2001 Baird ME, Lucas, DM, Mone AP, Waymer S, Warrell RP, Byrd JC, Grever MR."G3139 Promotes Release of IL-8 by Chronic Lymphocytic Leukemia Cells Cultured in vitro: Potential Implications for Therapeutic Use" . : 218b
January 2001 Aron JL, Murphy T, Parthun MR, Bannerji R, Kanakry C, Lucas, DM, Flinn IW, Marcucci G, Grever MR, Byrd JC."The Histone Deacetylase Inhibitor Depsipeptide (FR901228) Induces Apoptosis Via Activation of the Caspase 8 Pathway Concurrent with Lysine Specific Acetylation in Chronic Lymphocytic Leukemia Cells" . : 807a
January 2001 Lucas, DM Baird ME, Neuberg DS, Tallman MS, Flinn IW, Byrd JC, Grever MR."Importance of Culture Conditions for in vitro Chemosensitivity Assessment in Chronic Lymphocytic Leukemia Cells: Preliminary Results From Laboratory Studies, Eastern Cooperative Oncology Group Study 2997" . : 284b
January 2002 Pavletic SZ, Bociek G, Foran, J, Hatcher L, Rubocki R, Kuszynsky, C, Lucas, DM, Grever MR, Hock L, Joshi S. Hardiman P, Bierman P, Vose J, Armitage J, Talmage J."Immunological Effects of Pentostatin in a Minimally Myelosuppressive Regimen for Allogeneic Stem Cell Transplantation" . : 2446a
January 2002 Lucas, DM, Parthun MR, Mojica RD, Mone AP, Byrd JC, Grever MR."MS-275 Reduces Viability and Induces Changes in Histone Acetylaton in Cells From Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)." .
January 2002 Lucas, DM, Davis ME, Parthun MR, Mojica RC, Mone AP, Zwiesler J, Byrd JC, Grever MR."MS-275 Promotes Apoptosis in Cells from Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Concurrent with Inhibition of Histone Deactylase." . : 1500a
January 2002 Lucas, DM, Baird ME, Byrd JC, Tschumper RC, Jelinek DF, Kitada S, Reed JC, Rosenwald A, Staudt LM, Neuberg DS, Tallman MS, Flinn IW, Grever MR."ZAP70 and Caspase-3 Protein Expression Independently Associate with Immunoglobulin VH Gene Mutational Status in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)" . : 3168a
January 2002 Lin TS, Flinn IW, Lucas MS, Sickler J, Moran ME, Porcu P, Lucas, DM, Grever MR, Byrd JC."Filgrastim and Alemtuzumab (Campath-1H) for Refractory Chronic Lymphocytic Leukemia: High Frequency of Cytomegalovirus Disease and Delayed Neutropenia" . : 3168a
January 2002 Dewald GW, Paietta E, Goloubeva O, Bennett JM, Brockman SR, Paternoster SF, Lucas, DM, Neuberg DS, Flinn I, Tallman M, Grever MR, Byrd JC."Correlation of Interphase Fluorescence In Situ Hybridization (FISH) Abnomalies with Cell Morphology and Immunophenotyping in Chronic Lymphocytic Leukemia (B-CLL)." . : 2334a
January 2002 Mone AP, Lucas, DM, Aron JL, Cheney C, Johnson AJ, Bains SK, Tso JY, Weiner G, Green Je, Grever MR, Byrd JC."HU1D10 Induces Parallel Death and Survival Signals in Chronic Lymphocytic Leukemia Cells: Justification for Combination Studies of Hu1D10 with P13 Kinase Inhibitors" . : 1496a
January 2003 Lucas, DM, Zhang L, Freitas MA, Wickham J, Parthun MR, Davis ME, Marcucci G, Byrd JC, Grever MR."MS-275 Mediated Apoptosis and Generation of Reactive Oxygen Species Are Caspase Dependent in B-Cell Chronic Lymphocytic Leukemia (CLL)." . : 1566a
January 2003 Johnson AJ, Eisenbeis CF, Cheney CM, Mone AP, Lucas, DM, Byrd JC."Rituximab and 17-AAG Synergistically Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia (CLL)." . : 1594a
January 2003 Marcucci G, Stock W, Zwiebel JA, Cataland SR, Dai F, Moran M, Lucas, DM, Liu S, Klisovic MI, Kefauver C, Green M, Chan KK, Frankel SR, Grever MR, Byrd JC."Clinical Activity of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in Combination with Daunorubicin and Cytarabine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML)" . : 1398a
January 2003 Marcucci G, Dai G, Klisovic MI, Shen T, Liu S, Sher DA, Lucas, DM, Whitman SP, Vukosavljevic T, Zwiebel JA, Frankel SR, Grever MR, Stock W, Chan KK, Byrd JC."Pharmacologic and Biologic Assessment of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in Combination with Daunorubicin and Cytarabine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML)." . : 3254a
January 2004 Lucas, DM, Zhang L, Davis ME, Su X, Sklenar A, Parthun MR, Freitas MA, Kitada S, Reed JC, Marcucci G, Grever MR, Byrd JC."The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2." . : 2802a
January 2004 Lucas, DM, Dewald GW, Neuberg DS, Byrd JC, Lozanski G, Harbison J, Cunningham KD, Flinn IW, Tallman MS, Grever MR."Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Base" . : 949a
January 2004 Lin TS, Heerema NA, Swenor J, Lucas MS, Moran ME, Cheney CM, Lucas, DM, Young D, Caligiuri MA, Grever MR, Byrd JC."A Phase II Study of the TNF- Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities" . : 3469a
January 2004 Lin TS, Fischer B, Moran ME, Lucas, DM, Shank RS, Kraut EH, Farag SS, Lucas MS, Colevas AD, Grever MR, Byrd JC.."Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma" . : 2492a
January 2004 Lin TS, Biswas S, Naumovski L, Lecane P, Lucas MS, Moran ME, Mone AP,Lucas, DM."Phan S-C, Miller RA, Byrd, JC. Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL)." . : 3486a
January 2004 Grever MR, Lucas, DM, Dewald GW, Neuberg DS, Flinn IW, Tallman MS, Gribben JG, Byrd JC."Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997" . : 3487a
January 2004 Byrd JC, Lin TS, Dalton JT, Wu D, Fischer B, Moran ME, Blum KA, Shank RS, Lucas, DM, Lucas MS, Suarez J-R, Grever MR."Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL)" . : 341a
January 2004 Byrd JC, Gribben JG, Peterson B, Grever MR, Lozanski G, Lucas, DM, Larson RA, Caligiuri MA, Heerema NA."Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy" . : 476a
January 2004 Kitada S, Reed JC, Lucas, DMLucas DM, Neuberg DS, Gribben JG, Dewald GW, Flinn IW, Tallman MS, Byrd JC, Michael R. Grever MR.."Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment." . : 956a
January 2004 Motiwala T, Ghoshal K, Majumder S, Kutay H, Neuberg DS, Kitada S, Reed JC, Dewald GW, Flinn IW, Tallman MA, Liu T, Plass C, Lucas, DM, Byrd JC, Jacob ST, Grever MR."Methylation of the Tumor Suppressor Gene PTPRO (Receptor-Type Protein Tyrosine Phosphatase) Is Associated with Expression of Important Apoptosis-Related Proteins in Chronic Lymphocytic Leukemia (CLL)." . : 2804a
January 2005 Johnson AJ, Edwards R, Smith LL, Lucas, DM, Croce CM, Muthusamy N, Chen C-S, Liu Z, Chan KK, Grever MR, Byrd JC."The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia" . : 51a
January 2006 Johnson AJ, Wagner AJ, Smith LL,Lucas, DM, DeLay MD, Allison JM, Ivy SP, Lin TS, Byrd JC."The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL" . : 2101a
January 2006 Edwards RB, Lucas, DM, Lozanski G, Johnson AJ, Su B-N, Lin TS, Byrd JC, Kinghorn AD, Grever MR."Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata, Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells" . : 2600a
January 2006 Lucas, DM, Hussain S-R A, Johnson AJ, Smith LL, Wagner AJ, Allison JM, Guster SK, Lin TS, Byrd JC, Julian MW, Crouser ED, Grever MR."Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells" . : 2098a
January 2006 Lin TS, Lucas MS, Heerema NA, Matkovich JA, Moran ME, Cheney C, Lucas, DM, Young DC, Caligiuri MA, Grever MR, Byrd JC."A Phase II Study of the TNF- Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities" . : 2841a
January 2006 Browning RE,Lucas, DM, Geyer SM, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC."Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia" . : 2792a
January 2007 West DA, Lucas, DM, Davis ME, DeLay MD, Johnson AJ, Guster SK, Freitas MA, Parthun MR, Wang D, Kulp SK, Grever MR, Chen C-S, Byrd JC."The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia" . : 2101a
January 2007 DeLay MD, Johnson AJ, Lucas, DM, Durr DT, Sass EM, Goettl VM, Lehman A, Jarjoura D, Grever MR, Byrd JC."Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia" . : 3095a
January 2007 Lucas, DM, Edwards RB, DeLay MD, West DA, Lozanski G, Johnson AJ, Salim AA, Lin TS, Byrd JC, Kinghorn AD, Grever MR."The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL" . : 3123a
January 2008 Blum KA, Liu Z, Lucas, DM, Baiocchi RA, Lin TS, Benson D, Devine SM, Jones J, Andritsos L, Flynn J, Cheng P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC.."A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation." . : 3169a
January 2008 Hertlein E, West DA, Craig RW, Lucas, DM, Byrd JC."NF- B Is Active in Mcl-1 Promoter Regulation in Human CLL" . : 2625a
January 2008 Alinari L, Hertlein E, Goldenberg DM, Lapalombella R, Yan F, Zhang X, Lucas, DM, Muthusamy N, Byrd JC, Baiocchi RA.."Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma" . : 886a
January 2009 Hertlein E, Triantafillou G, Hessler J, Zhang X, Jarjoura D, Lucas, DM, Lee RJ, Muthusamy N, Goldenberg DM, Byrd JC."Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells" . : 721a
January 2009 Lucas, DM, Sass EJ, Edwards RB, Pan L, Lozanski G, Heerema NA, Byrd JC, Kinghorn AD, Grever MR.."Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression" . : 1737a
January 2009 Flynn JM, Johnson AJ, Andritsos L, Blum KA, Jones JA, Wiley EA, Hu W, Hessler J, Smith LL, Lucas, DM, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC."The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia" . : 886a
December 2010 Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, Litzow MR, Rowe JM, Lucas, DM, Kitada S, Jelinek DF, Gribben JG, Byrd JC, Reed JC, Hussein MA, Appelbaum FR, Larson RA, Moore Jr DF, Tallman MS."Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997" Orlando. : 924
December 2010 Mahoney E, Johnson AJ, Wagner AJ, Hessler J, Gupta SV, Herman SEM, Andritsos L, Jones JA, Flynn JM, Lucas, DM, Grever MR, Byrd JC."Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol." Orlando. : 691
December 2010 Hertlein EK, Yu L, Zhang J, Johnson AJ, Lucas, DM, Marcucci G, Jarjoura D, Byrd JC."Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease" Orlando. : 3642
July 2011 Lucas, DM, Lapo Alinari, John T. Patton, A. Douglas Kinghorn, Robert A. Baiocchi, Michael R. Grever."The Protein Synthesis Inhibitor Silvestrol Has In Vitro and In Vivo Efficacy in Aggressive B-cell Malignancies" Washington.
July 2011 Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Chan KK, Kinghorn AD, Grever MR, Phelps MA, Lucas, DM."Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with rapamycin" Chicago.
December 2011 Gupta SV, Hertlein EK, Woyach JA, Sass EJ, Davis ME, Byrd JC, Lucas DM.Lucas, DM."The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF- B Response" San Diego.
May 2011 Kogure, T; Braconi, C; Lucas, DM; Grever, M; Kinghorn, AD; Patel, T."Therapeutic Efficacy of Silvestrol, a Novel Protein Translation Inhibitor, as an Anticancer Agent for Cholangiocarcinoma" . : S913
December 2011 Alinari L, Edwards RB, Prince CJ, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA, Lucas, DM."Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol." San Diego.
December 2011 Alachkar H, Santhanam R, Lucas, DM, Schwind S, Hickey C, Pang J, Perrotti D, Pan L, Kinghorn AD, Marcucci G, Grever MR.."Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML)." San Diego.
April 2011 Alachkar H, Liu S, Schwind S, Becker H, Metzeler KH, Hickey C, Pang J, Whitman SP, Chan KK, Garzon R, Lucas DM, Perrotti D, Wu L-C, Grever MR, Kinghorn AD, Marcucci G.."The natural oridyct silvestrol decreases oncogenic FLT3 and miR-155 levels in FLT3-ITD positive Acute Myeloid Leukemia (AML) cells" Orlando.
December 2011 Patton JT, Lustberg ME, Garman SL, Kinghorn AD, Pan L, Lucas, DM, Grever MR, Baiocchi RA."Silvestrol Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas While Sparing Innate and Antigen Specific Adaptive Immunity" San Diego.

Inventions and Patents

Baiocchi, Robert; Patton, John; Lucas, DM; Grever, Michael; 'Douglas Kinghorn'. "“Immune Modulatory Properties of Silverstrol”." Filed July 2011.

 

Presentations

"The Protein Synthesis Inhibitor Silvestrol has In Vitro and In Vivo Efficacy in Aggressive B-cell Malignancies." Presented at NCI Translational Science Meeting, Washington, DC. (July 2011)

 

Professional Activities

2010 - present Light the Night. Leukemia & Lymphoma Society.
2012 - present American Cancer Society Seed Grant. American Cancer Society.
2010 Pelotonia. OSUCCC/James Cancer Hospital.